Stock Track | Progyny Plunges 5.71% in Pre-Market on Disappointing Growth Outlook and Client Loss

Stock Track02-27 21:18

Progyny's stock fell sharply by 5.71% during pre-market trading on Friday, extending losses from the previous session.

The decline follows the company's latest financial update released post-market on Thursday, which revealed a concerning growth trajectory. Investors reacted negatively to Progyny's projection of slower revenue growth for fiscal year 2026, estimated between 5.1% and 9%, a deceleration from the 10% growth achieved in 2025. Furthermore, first-quarter 2026 revenue growth guidance of just 2.5% fell significantly below analyst expectations.

Additional pressure stemmed from the confirmed loss of a large client that did not renew its contract for 2025, resulting in no revenue contribution in the fourth quarter. The company's pharmacy benefit services segment also reported a 1.1% revenue decline during the quarter, raising further concerns about the stability of its business lines.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment